R&D pipeline progressing well
20/11/20 -"Better than expected performance of Tepezza and the upcoming launch of Amivantamab should bolster Genmab’s top line in the near term. Moreover, encouraging clinical data for pipeline assets, ..."
Pages
54
Language
English
Published on
20/11/20
You may also be interested by these reports :
29/10/26
After increasing both our DCF and NAV estimates by >20% (discussed in the respective sections), we maintain a Reduce recommendation with c.2% ...
28/10/26
The Q3 profitability exceeded expectations, though sales came in line with consensus. The strong showing in ‘Specialty medicines’ made up for the ...
28/10/26
The Q3 sales missed consensus because of near-term biosimilar supply constraints, pricing pressure in Germany and lower prices for penicillin APIs – ...
27/10/26
The Q3 results were ahead of the street’s expectations, as generic erosion of a major heart failure drug was more than compensated for by robust ...